Chang Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Chang Liu has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Linnan Zhu
Biomedical Pioneering Innovation Center (BIOPIC) and School of Life Sciences, Peking University, Beijing 100871, China
16 shared publications - Zemin Zhang
Institute for Data-Driven Tumor Immunology, Chongqing Medical University, Chongqing, China.
16 shared publications - Dan Tong
Changping Laboratory, Beijing, China
15 shared publications - Dongfang Wang
Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, PR China
15 shared publications - Guohui Dang
Changping Laboratory, Beijing, China
15 shared publications - Hongtao Fan
Peking University 1 Biomedical Pioneering Innovative Center (BIOPIC), Academy for Advanced Interdisciplinary Studies, School of Life Sciences, State Key Laboratory of Metabolic Dysregulation and Prevention and Treatment of Esophageal Cancer Beijing, China
15 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S4 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
Table S4. GO enrichment analysis of human LRRC15+ CAFs from lung cancer, based on scRNA-seq data, related to Figure 5C
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
Table S4. GO enrichment analysis of human LRRC15+ CAFs from lung cancer, based on scRNA-seq data, related to Figure 5C
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
Figure S4 LRRC15 deficiency induces broad immune alterations in mouse tumors, related to Figure 3
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
Figure S4 LRRC15 deficiency induces broad immune alterations in mouse tumors, related to Figure 3
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
Table S2. Summary of scRNA-seq Datasets of Lung Cancer Stromal Cells, related to Figs. 1, 3, 5, S1, S2, and S8
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
Table S2. Summary of scRNA-seq Datasets of Lung Cancer Stromal Cells, related to Figs. 1, 3, 5, S1, S2, and S8
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
Table S1. Clinical information of lung cancer patients, related to Figures 1, 3, 4, 5, S2, S6 and S7
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
Table S1. Clinical information of lung cancer patients, related to Figures 1, 3, 4, 5, S2, S6 and S7
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
Figure S8 Targeting LRRC15+ CAFs attenuates tumor progression, related to Figure 6
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
Figure S8 Targeting LRRC15+ CAFs attenuates tumor progression, related to Figure 6
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
Figure S3 LRRC15 promotes tumor progression by modulating immune responses, related to Figure 2
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
Figure S3 LRRC15 promotes tumor progression by modulating immune responses, related to Figure 2
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S5 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
Table S5. GO enrichment analysis of mouse LRRC15+ CAFs from TC1-GFP tumor co-injected with TGF-β-treated CAFs, based on scRNA-seq data, related to Figure 5D
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
Table S5. GO enrichment analysis of mouse LRRC15+ CAFs from TC1-GFP tumor co-injected with TGF-β-treated CAFs, based on scRNA-seq data, related to Figure 5D
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
Figure S2 LRRC15 expression correlates with poor prognosis in cancer patients, related to Figure 1
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
Figure S2 LRRC15 expression correlates with poor prognosis in cancer patients, related to Figure 1
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
Figure S7 LRRC15 in CAFs promotes macrophage M2 polarization via ECM, related to Figure 5
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
Figure S7 LRRC15 in CAFs promotes macrophage M2 polarization via ECM, related to Figure 5